News Room

All Press Releases In The News Blogs
15 May 2018
Press Release
Dutch Company Xenikos Secures USD 30 Million in Series B Financing 
Xenikos
08 May 2018
Press Release
Palladio Biosciences Receives FDA IND Clearance to Begin the ELiSA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
30 Apr 2018
Press Release
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines 
Synthorx - Acquired by Sanofi (EURONEXT:SAN)
26 Apr 2018
Press Release
Further MP0250 clinical data and partner interest underline Molecular Partners’ continued progress of its proprietary oncology compounds 
Molecular Partners (S​wiss​: MOLN.SW)
17 Apr 2018
In The News
The Medicine Maker
Celebrating the World’s Top 100 Medicine Makers 
11 Apr 2018
Press Release
Molecular Partners and AstraZeneca announce collaboration on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated NSCLC 
Molecular Partners (S​wiss​: MOLN.SW)
22 Mar 2018
In The News
PR Newswire
Human Vaccines Project Appoints Dr. Moncef Slaoui as New Board Member 
20 Mar 2018
In The News
FierceBiotech
Medicxi founds biotech creation engine C21Med 
19 Mar 2018
Press Release
Medicxi unveils ‘The Foundation Institute’
19 Mar 2018
Blog
The Making of Medicxi: We have the Operating Partner
by Francesco De Rubertis
14 Mar 2018
In The News
BioWorld
BIO-Europe Spring Academic scientist injects dose of reality into microbiome debate 
09 Mar 2018
In The News
BioCentury
Reviving Lixivaptan 
26 Feb 2018
Press Release
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF 
ObsEva (NASDAQ: OBSV)
20 Feb 2018
Press Release
Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology 
Egalet (NASDAQ:EGLT)
20 Feb 2018
Press Release
GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology 
Gensight (Euronext: SIGHT)
19 Feb 2018
Press Release
Molecular Partners’ collaboration partner Allergan exercises the third option for a DARPin® product candidate in ophthalmology 
Molecular Partners (S​wiss​: MOLN.SW)
13 Feb 2018
Press Release
Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors 
Sequenta  - Acquired by Adaptive Biotechnologies
08 Feb 2018
Press Release
Molecular Partners reports significant progress of pipeline and preliminary unaudited key financials for 2017 – Key value inflection points in 2018 
Molecular Partners (S​wiss​: MOLN.SW)
05 Feb 2018
Press Release
Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director 
Minerva Neurosciences (NASDAQ: NERV)
03 Feb 2018
In The News
Le Temps
Grande Interview - Francesco De Rubertis 
29 Jan 2018
Press Release
Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal 
Egalet (NASDAQ:EGLT)
25 Jan 2018
Press Release
GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update 
Gensight (Euronext: SIGHT)
25 Jan 2018
Press Release
GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing 
Gensight (Euronext: SIGHT)
24 Jan 2018
Press Release
Egalet to Co-Host Category 1 Focus Group 
Egalet (NASDAQ:EGLT)
23 Jan 2018
Press Release
Egalet's Partner OraPharma Begins Promotion of SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
10 Jan 2018
Press Release
GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa 
Gensight (Euronext: SIGHT)
08 Jan 2018
Press Release
Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma 
Molecular Partners (S​wiss​: MOLN.SW)
08 Jan 2018
In The News
Biotech Finances
Europe: Les Biotechs Early Stage Plus Attractives Que Jamais 
07 Jan 2018
In The News
Reuters
Celgene to buy Impact Biomedicines for up to $7 billion 
07 Jan 2018
Press Release
Celgene to acquire Impact Biomedicines, adding Fedratinib to its pipeline of novel therapies for hematologic malignancies 
Impact Biomedicines - Acquired by BMS (NASDAQ:BMY)
06 Jan 2018
Blog
Everyone Goes Home with a Balloon - Impact Biomedicines
by Kevin Johnson
04 Jan 2018
Press Release
Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease 
Sequenta  - Acquired by Adaptive Biotechnologies
03 Jan 2018
Press Release
Molecular Partners’ collaboration partner Allergan exercises options for two DARPin® product candidates 
Molecular Partners (S​wiss​: MOLN.SW)
03 Jan 2018
Press Release
Egalet Partners with OraPharma to Co-Promote SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
21 Dec 2017
Press Release
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder 
Minerva Neurosciences (NASDAQ: NERV)
15 Dec 2017
Press Release
Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain 
Egalet (NASDAQ:EGLT)
11 Dec 2017
Press Release
Minerva Neurosciences Names Richard Russell President 
Minerva Neurosciences (NASDAQ: NERV)
11 Dec 2017
Press Release
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors 
Minerva Neurosciences (NASDAQ: NERV)
06 Dec 2017
Press Release
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder 
Minerva Neurosciences (NASDAQ: NERV)
05 Dec 2017
Press Release
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor 
ObsEva (NASDAQ: OBSV)
05 Dec 2017
Press Release
GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
30 Nov 2017
In The News
Bloomberg
The Bloomberg 50 - From finance and politics to tech and entertainment, these people defined global business in 2017 
28 Nov 2017
Press Release
Egalet Announces Positive Top-Line Results from Phase 3 Study Evaluating Efficacy and Safety of Egalet-002 in Patients with Moderate-to-Severe Chronic Low Back Pain 
Egalet (NASDAQ:EGLT)
20 Nov 2017
Press Release
Egalet Received a Grant from InnoBooster to Develop a Novel Application of Guardian™ Technology 
Egalet (NASDAQ:EGLT)
16 Nov 2017
Press Release
Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002 
Egalet (NASDAQ:EGLT)
09 Nov 2017
Press Release
Molecular Partners expands and advances robust pipeline of DARPin® therapies in oncology and ophthalmology 
Molecular Partners (S​wiss​: MOLN.SW)
07 Nov 2017
Press Release
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis 
ObsEva (NASDAQ: OBSV)
06 Nov 2017
Press Release
Egalet Announces ARYMO ER Added to Large Payer Medicare Part D Formulary 
Egalet (NASDAQ:EGLT)
01 Nov 2017
Press Release
Palladio Biosciences Announces Presentations of New Data for Lixivaptan and Polycystic Kidney Disease during the American Society of Nephrology 2017 Annual Meeting 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
31 Oct 2017
Press Release
Shareholders of Molecular Partners approved the elections of Bill Burns and Patrick Amstutz to the Board of Directors 
Molecular Partners (S​wiss​: MOLN.SW)
31 Oct 2017
Press Release
Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy 
Minerva Neurosciences (NASDAQ: NERV)
26 Oct 2017
Press Release
Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions 
Versartis (NASDAQ: VSAR)
26 Oct 2017
Press Release
GenSight Biologics Reports its Cash Position as of September 30, 2017 
Gensight (Euronext: SIGHT)
25 Oct 2017
Press Release
GenSight Biologics Appoints Barrett Katz as Chief Medical Officer 
Gensight (Euronext: SIGHT)
13 Oct 2017
Press Release
Startup Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients 
Impact Biomedicines - Acquired by BMS (NASDAQ:BMY)
12 Oct 2017
Press Release
First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP0274 
Molecular Partners (S​wiss​: MOLN.SW)
12 Oct 2017
In The News
Business Wire
Gadeta Strengthens Executive Management Team with the Appointments of Shelley Margetson as CEO & Thomas Davis as CMO 
11 Oct 2017
Press Release
University of Toronto and Medicxi launch Janpix Inc. with US $19M in funding to advance Dual Impact Cancer Therapies 
Janpix - Centessa Therapeutics (NASDAQ:CNTA)
10 Oct 2017
Press Release
ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors 
ObsEva (NASDAQ: OBSV)
04 Oct 2017
Press Release
Palladio Biosciences Receives Orphan Drug Designation from the U.S. FDA for Lixivaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
03 Oct 2017
Press Release
Bill Burns nominated for election to Molecular Partners’ Board of Directors as Vice-Chairman with nomination to Chairman in 2018 
Molecular Partners (S​wiss​: MOLN.SW)
02 Oct 2017
Press Release
GenSight Biologics integrates the Enternext® PEA-PME 150 index 
Gensight (Euronext: SIGHT)
21 Sep 2017
Press Release
Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint 
Versartis (NASDAQ: VSAR)
19 Sep 2017
Press Release
GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes 
Gensight (Euronext: SIGHT)
19 Sep 2017
Press Release
Moncef Slaoui joins Medicxi
18 Sep 2017
Press Release
National Lacrosse League and Egalet Corporation Announce Educational Partnership Around A Non-Narcotic Pain Option and Responsible Pain Management 
Egalet (NASDAQ:EGLT)
14 Sep 2017
In The News
B3C Newswire
Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain 
14 Sep 2017
In The News
Kent Online
Joint-pain treatment set for human trials after development by Levicept in Discovery Park in Sandwich 
14 Sep 2017
Press Release
Levicept Starts First-in-Human Phase I Trial of LEVI-04, A Novel Fusion Protein Therapy for Chronic Pain 
Levicept
11 Sep 2017
Press Release
Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development 
Minerva Neurosciences (NASDAQ: NERV)
10 Sep 2017
In The News
Le Temps
«Les Suisses se méfient encore du capital-risque» 
08 Sep 2017
Press Release
Egalet Presented New Data at PAINWEEK Demonstrating Potential of ARYMO ER to Deter Opioid Abuse 
Egalet (NASDAQ:EGLT)
06 Sep 2017
Press Release
ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule 
ObsEva (NASDAQ: OBSV)
05 Sep 2017
Press Release
Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs 
Versartis (NASDAQ: VSAR)
05 Sep 2017
Press Release
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder 
Minerva Neurosciences (NASDAQ: NERV)
05 Sep 2017
Press Release
Egalet's Partner Ascend Therapeutics® U.S., LLC Begins Promotion of SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
04 Sep 2017
In The News
Labiotech.eu
Meet this Blockbuster Developer turned Partner at a Headlining VC 
30 Aug 2017
Press Release
Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead 
Molecular Partners (S​wiss​: MOLN.SW)
25 Aug 2017
Press Release
Minerva Neurosciences Announces European Commission Approval of Amendment of MIN-202 Agreement With Janssen 
Minerva Neurosciences (NASDAQ: NERV)
01 Aug 2017
Press Release
GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy 
Gensight (Euronext: SIGHT)
05 Jul 2017
Press Release
Diasome Pharmaceuticals, Inc. Receives Funding From JDRF T1D Fund 
Diasome
05 Jul 2017
In The News
BioCentury Innovations
Diasome Raises $30M in Series A Round 
05 Jul 2017
In The News
Business Wire
Diasome Pharmaceuticals, Inc. Receives Funding Led By Medicxi 
23 Jun 2017
Press Release
GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe 
Gensight (Euronext: SIGHT)
22 Jun 2017
Press Release
Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia 
Minerva Neurosciences (NASDAQ: NERV)
20 Jun 2017
Press Release
Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO 
Egalet (NASDAQ:EGLT)
15 Jun 2017
Press Release
Medicxi launches first $300m late-stage life sciences fund Medicxi Growth 1 (MG1), backed by Novartis and Verily
15 Jun 2017
Blog
Introducing Medicxi Growth 1, Our First $300m Late-Stage Fund
by Giuseppe Zocco
14 Jun 2017
Press Release
GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
07 Jun 2017
Press Release
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy 
ObsEva (NASDAQ: OBSV)
07 Jun 2017
Press Release
Egalet Partners with Ascend Therapeutics® U.S., LLC to Co-Promote SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
30 May 2017
Press Release
Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250 
Molecular Partners (S​wiss​: MOLN.SW)
23 May 2017
Press Release
Palladio Biosciences Formed to Develop Transformative Medicines for Orphan Diseases of the Kidney 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
22 May 2017
Press Release
Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology 
Versartis (NASDAQ: VSAR)
18 May 2017
Press Release
ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 
ObsEva (NASDAQ: OBSV)
18 May 2017
Press Release
ObsEva Reports First Quarter 2017 Financial Results and Business Update 
ObsEva (NASDAQ: OBSV)
18 May 2017
Press Release
Egalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysis 
Egalet (NASDAQ:EGLT)
17 May 2017
Press Release
Egalet Announces ARYMO™ ER Data Published in Journal of Opioid Management and American Journal of Drug and Alcohol Abuse 
Egalet (NASDAQ:EGLT)
15 May 2017
Press Release
Egalet Announces Scientific Presentations at American Pain Society Meeting 
Egalet (NASDAQ:EGLT)
15 May 2017
Press Release
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA 
Minerva Neurosciences (NASDAQ: NERV)